ADENOSCAN FOR IV INFUSION 3 mg/ml

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

ADENOSINE

Available from:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

ATC code:

C01EB10

Dosage:

3 mg/ml

Pharmaceutical form:

INJECTION

Administration route:

INTRAVENOUS

Prescription type:

Prescription Only

Manufactured by:

GLAXO WELLCOME PRODUCTION

Authorization date:

1999-04-08

Patient Information leaflet

ADENOSCAN
®

Adenosine 
Solution for Infusion 
[sanofi logo] 
PRESENTATION

Adenoscan is a sterile solution for intravenous infusion provided
in clear glass vials. Each vial contains 30 
mg of adenosine in 10 ml of a 0.9% w/v solution of Sodium
Chloride Ph Eur in Sterile Water for Injections 
Ph Eur. 
USES

Intravenous Adenoscan is a coronary vasodilator for use in
conjunction with radionuclide myocardial 
perfusion imaging in patients who cannot exercise adequately or for
whom exercise is inappropriate. 
_MODE OF ACTION_

Adenoscan administered by intravenous infusion induces coronary
hyperaemia which is limited in areas 
of myocardium supplied by significantly stenosed arteries,
and heterogeneous myocardial perfusion 
results. 
DOSAGE AND ADMINISTRATION

Adenoscan is intended for use in hospitals, where facilities for
cardiac monitoring and resuscitation are 
available. 
It should be administered following the same procedure as for
exercise testing where facilities for cardiac 
monitoring and cardio-respiratory resuscitation are
available. During administration of Adenoscan 
continuous ECG control is necessary as life-threatening arrhythmia
might occur. Heart rate and blood 
pressure should be monitored every minute. 
_ADULTS_

1.  Adenoscan should be administered as a continuous peripheral
intravenous infusion at a dose of 140 
µg/kg/min for six minutes (total dose 0.84 mg/kg) using an
infusion pump. Separate venous sites for 
Adenoscan and radionuclide administration are recommended to avoid an
adenosine bolus effect. 
2.  After three minutes of Adenoscan infusion, the radionuclide is
injected. 
3.  Heart rate and blood pressure should be recorded at 1 minute
intervals, and ECG should be 
monitored continuously during Adenoscan infusion. To avoid an
adenosine bolus effect, blood 
pressure should be measured in the arm opposite to the Adenoscan
infusion. 
The table below is given as a guide for adjustment of the